talactoferrin alfa has been researched along with Benign Neoplasms in 3 studies
talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six patients with metastatic cancer who had progressed on, or were ineligible for, standard chemotherapy received single-agent oral talactoferrin." | 2.75 | Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors. ( Falchook, GS; Hayes, TG; Varadhachary, A, 2010) |
| "Lactoferrin is an iron-binding glycoprotein first identified in breast milk as a protein product of mammary epithelial cells." | 2.72 | Phase I trial of oral talactoferrin alfa in refractory solid tumors. ( Davis, LD; Dhingra, HM; Falchook, GF; Hayes, BP; Hayes, TG; Smith, DP; Varadhachary, A; Varadhachary, GR, 2006) |
| "Thus, the inhibition of distant tumors by oral TLF seems to be mediated by an IFN-gamma-dependent enhancement of CD8(+) T- and NKT cell activity initiated within the intestinal mucosa." | 1.34 | Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. ( Blezinger, P; Cavallo, F; Curcio, C; Engelmayer, J; Forni, G; Pericle, F; Spadaro, M; Varadhachary, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayes, TG | 2 |
| Falchook, GS | 1 |
| Varadhachary, A | 3 |
| Falchook, GF | 1 |
| Varadhachary, GR | 1 |
| Smith, DP | 1 |
| Davis, LD | 1 |
| Dhingra, HM | 1 |
| Hayes, BP | 1 |
| Spadaro, M | 1 |
| Curcio, C | 1 |
| Cavallo, F | 1 |
| Engelmayer, J | 1 |
| Blezinger, P | 1 |
| Pericle, F | 1 |
| Forni, G | 1 |
2 trials available for talactoferrin alfa and Benign Neoplasms
| Article | Year |
|---|---|
Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal | 2010 |
Phase I trial of oral talactoferrin alfa in refractory solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Humans; Interleukin-18; Lactoferrin; Male; Middle | 2006 |
1 other study available for talactoferrin alfa and Benign Neoplasms
| Article | Year |
|---|---|
Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Fe | 2007 |